Arcturus Therapeutics Holdings Inc.
10628 Science Center Drive
Suite 250
San Diego, CA 92121
United States
858 900 2660
https://arcturusrx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 180
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Joseph E. Payne M.Sc. | Founder, President, CEO & Director | 906.5k | 無 | 1972 |
| Dr. Padmanabh Chivukula Ph.D. | Founder, Chief Scientific Officer, COO & Secretary | 687.5k | 無 | 1979 |
| Mr. Andrew H. Sassine MBA | CFO & Director | 687.5k | 無 | 1964 |
| Mr. Lance Kurata | Chief Legal Officer | 600k | 無 | 無 |
| Ms. Neda Safarzadeh | Vice President and Head of IR/PR & Marketing | 無 | 無 | 無 |
| Ms. Natash O. Bowman | Chief Human Resources Officer | 無 | 無 | 無 |
| Mr. Kevin T. Skol | Chief Business Officer | 無 | 無 | 無 |
| Dr. Juergen Froehlich FCPh, M.D., MBA | Chief Medical Officer | 無 | 無 | 1956 |
| Dr. Igor Smolenov M.D., Ph.D. | Chief Development Officer | 無 | 無 | 無 |
| Joseph Roberts | Controller | 無 | 無 | 無 |
描述
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
公司管治
截至 2024年5月1日 止，Arcturus Therapeutics Holdings Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：9；董事會：4；股東權利：6；現金賠償：10。
